J&J, Boston Scientific release drug-coated stent safety reports

10/21/2007 | Bloomberg

Patients who received Johnson & Johnson's drug-coated stent Cypher have lower rates of blood clot recurrence compared with those who received bare-metal devices, while Boston Scientific Corp.'s Taxus stent was found to be as safe after two years for use in sicker heart patients as for use in those who were healthier, according to studies presented at a conference in Washington, D.C. "[Drug-eluting] stent safety is a hot-button topic, and the big question we see coming out of the meeting will be whether utilization picks back up," a market analyst said.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN